-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, at the American Society of Clinical Oncology in 2021, Novartis announced the latest phase 2 clinical trial data of the oral highly selective small molecule MET inhibitor Tabrecta in the treatment of adult patients with metastatic non-small cell lung cancer
.
These patients carry genetic mutations that cause the skipping of exon 14 of the MET gene
Recently, at the American Society of Clinical Oncology in 2021, Novartis announced the latest phase 2 clinical trial data of the oral highly selective small molecule MET inhibitor Tabrecta in the treatment of adult patients with metastatic non-small cell lung cancer
.
These patients carry genetic mutations that cause the skipping of exon 14 of the MET gene